HaemaLogiX has appointed Dr Chris Baldwin as Chief Executive Officer and Managing Director, marking a significant leadership transition as the company prepares for its next stage of clinical and corporate development.
Dr Baldwin formally commenced in the role on 5 January 2026, bringing more than two decades of experience across scientific research, global operations, capital markets and commercial strategy. His appointment comes at a pivotal moment for HaemaLogiX, which is advancing a novel immunotherapy platform to address significant unmet needs in blood cancers and B-cell diseases.
With a PhD in Chemical Engineering from the University of Cambridge, Dr Baldwin was selected as a British Marshall Scholar before beginning his career in academia as an Associate Professor at Iowa State University. He later transitioned into industry, joining McKinsey & Company in New York, where he advised global organisations on strategy and transformation. His career has spanned founder and C-suite roles across ASX-listed and international biotechnology, precision therapeutics and high-technology companies.
Dr Baldwin has led corporate strategy, capital raising, investor engagement, partnership formation and product launches across multiple geographies, including Australia, Asia-Pacific, Europe and the United States. He also brings deep operational experience, having managed Asia-Pacific profit-and-loss portfolios with leading medical device companies Terumo BCT and Haemonetics.
Executive Chairman John Cullity said the Board was confident the appointment would strengthen the company’s foundations as it moves into 2026.
“Chris brings a rare combination of deep scientific expertise and global commercial leadership,” he said. “His execution-focused approach and proven track record across healthcare, biotechnology and technology-led organisations position HaemaLogiX well as we advance our clinical programs and prepare for key corporate milestones, including our planned IPO.”
“HaemaLogiX has built a compelling immunotherapy platform with the potential to address significant unmet needs for patients with blood cancers,” said Dr Baldwin. “I am excited to join the company at this important stage of growth and to work with the Board and team to advance our clinical programs, build strategic partnerships and create long-term value for patients and investors.”